Use Sativex as an adjunct
when patients’ first-line oral
anti-spasticity medications
are not enough1–3

When to prescribe

Sativex should be
before resorting
to invasive

Sativex is indicated as treatment for symptom improvement in adult patients with moderate to severe spasticity due to MS who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity-related symptoms during an initial trial of therapy1

Patients should be offered a 4-week trial of Sativex to assess their response1

Those who achieve a ≥20% improvement in spasticity-related symptoms may continue with treatment1

See how many patients responded to treatment with Sativex